Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $342.00 at Scotiabank

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Scotiabank from $338.00 to $342.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday. Sanford C. Bernstein cut their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $316.25.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $266.83 on Monday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market cap of $34.71 billion, a P/E ratio of -122.96 and a beta of 0.30. The stock’s fifty day moving average price is $260.16 and its 200-day moving average price is $260.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently bought and sold shares of ALNY. Larson Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. Finally, Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.